Inari Medical (NARI)
(Delayed Data from NSDQ)
$45.07 USD
+0.27 (0.60%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $45.08 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
NARI 45.07 +0.27(0.60%)
Will NARI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NARI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NARI
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
Inari Medical (NARI) Q2 Earnings Miss, Revenues Increase Y/Y
NARI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inari Medical, Inc. (NARI) Reports Q2 Loss, Tops Revenue Estimates
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
Other News for NARI
What's Driving Inspire Medical Systems Inc's Surprising 26% Stock Rally?
Inari Medical: A Strong Buy on Robust Product Reception and Promising Financial Outlook
What's Driving Inspire Medical Systems Inc's Surprising 19% Stock Rally?
Boeing downgraded, Southwest upgraded: Wall Street's top analyst calls
Inari Medical: Navigating Competitive Threats and Growth Potential in Venous Thromboembolism Treatment